HEME Healthmed Services Ltd (PK)

HealthMed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce that its recently-acquired subsidiary, DRS Technologies, Inc., has been merged with and into HealthMed Services, Ltd.

The merger, which took effect on June 6, 2011, was completed in order to fully absorb into the Company the proprietary technology of DRS Technology. The DRS Technology business model is to distribute and market diabetes test kits through retail outlets and online, enabling consumers in a totally confidential manner to predict their propensity to contract diabetes based on testing their saliva to detect certain significant proteins that may be present. Results of the tests are available online only to the individual purchaser of a test kit through confidential codes provided in the kit, without revealing the identity of the user to anyone.

About HealthMed Services, Ltd.

The Company has acquired the rights from Dr. Henry J. Smith to an improved Donor Organ Transport System (Patent Pending). By reconditioning the donor organ such as the heart, kidney or liver and extending the period of time for transport, it will be possible to improve the success rates of transplants. Also, by having a device that can maintain the organ for an extended period in vitro, it will be possible to test drugs on isolated organs in vitro before starting clinical trials on patients. The Company has made significant progress in its research program and has a working model of a portable organ transport device. Dr. Smith has completed the initial research studies showing that isolated donor organs could be kept alive for an extended period of time using the organ transport system developed. Research has indicated this device to be what is needed and desired for the practice of medicine, and it represents strong possibility to be the foundation for an enterprise highly profitable to the Company and its shareholders. In addition, the Company has recently expanded its business model to include a confidential testing program for individuals to test for the propensity to contract diabetes.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with cleaning fluid and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, quarterly reports or current reports filed from time-to-time with OTC Markets, Inc.

Contact: Richard E. Floegel (619) 248-6868